Barclays Reiterates an 'Equalweight' on Corporate Executive Board (EXBD); Generally In line 1Q; Recovery Priced In
Tweet Send to a Friend
Barclays reiterates an 'Equalweight' on Corporate Executive Board (NASDAQ: EXBD), PT $39.
Barclays analyst says, "Last night, EXBD reported solid ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Barclays analyst says, "Last night, EXBD reported solid ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
